Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lifted by equities researchers at Wells Fargo & Company from $170.00 to $235.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 30.15% from the company’s current price.

A number of other research firms have also issued reports on JAZZ. The Goldman Sachs Group boosted their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. JPMorgan Chase & Co. decreased their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Royal Bank Of Canada set a $194.00 price objective on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $195.07.

Jazz Pharmaceuticals Stock Up 6.2%

Shares of NASDAQ:JAZZ traded up $10.48 during midday trading on Tuesday, hitting $180.57. 2,401,747 shares of the company’s stock traded hands, compared to its average volume of 928,761. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $180.97. The company has a market cap of $10.97 billion, a PE ratio of -26.90, a P/E/G ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The firm’s fifty day moving average price is $134.88 and its two-hundred day moving average price is $120.76.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the previous year, the company posted $6.54 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities research analysts anticipate that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently made changes to their positions in the company. CWM LLC increased its position in shares of Jazz Pharmaceuticals by 56.2% during the 1st quarter. CWM LLC now owns 1,259 shares of the specialty pharmaceutical company’s stock worth $156,000 after purchasing an additional 453 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in Jazz Pharmaceuticals by 269.5% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 9,721 shares of the specialty pharmaceutical company’s stock worth $1,207,000 after buying an additional 7,090 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $10,900,000. KLP Kapitalforvaltning AS grew its position in shares of Jazz Pharmaceuticals by 1.8% during the 1st quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock worth $2,148,000 after purchasing an additional 300 shares in the last quarter. Finally, Readystate Asset Management LP increased its holdings in shares of Jazz Pharmaceuticals by 7.7% during the first quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 1,635 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.